Ajanta Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+17.3%+10.4%+12.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+10.7%+7.5%+49.6%
+9.5%+7.6%+58.9%
+14.7%+12.8%+38.8%
+14.9%+13.5%+41.3%
+22.7%+8.1%−0.9%
+19.4%+6.2%+5.3%
−54.3%+47.4%−0.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AJANTPHARM₹3,285.00

Ajanta Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALKEMIPCALABTORNTPHARMABBOTINDIAANTHEMGLAXOMEDANTAGLENMARKMcap ₹41,177 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+12.5+10.4+17.3—
EBITDA Growth—+49.6+7.5+10.7—
EBIT Growth—+58.9+7.6+9.5—
Net Income Growth—+38.8+12.8+14.7—
EPS Growth—+41.3+13.5+14.9—
Total Assets Growth—-0.9+8.1+22.7—
Total Equity Growth—+5.3+6.2+19.4—
Cash from Operations Growth—-0.8+47.4-54.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.